A New T-Cell activation assay based on Hyris qPCR Technology marks a disruptive approach for the detection of SARS-CoV-2 specific cellular immunity LONDON, June 15, 2022 (GLOBE NEWSWIRE) -- With over 460 million global cases thus far, 6 million of which have resulted in death, the COVID-19 pandemic from SARS-CoV-2 proved to be a dire health...

Hyris Fully Embraces the Immunology Sector to Better Fight COVID-19 and Beyond, Presenting Its New, Disruptive T-Cell Test to the International Conference 'A-Wish' LONDON, Dec. 15, 2021 (GLOBE NEWSWIRE) -- As the COVID-19 pandemic keeps causing concerns, with new variants spreading worldwide, it is now widely recognized that we must move beyond a...